SCHEMBL4853173

SCHEMBL4853173

CCC(=O)NCc1ccc(C(F)(F)F)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.49
NAMPT P43490 2/20 0.48
KCNQ3 O43525 1/20 0.47
KCNQ2 O43526 1/20 0.47
KCNQ4 P56696 1/20 0.47
KCNQ5 Q9NR82 1/20 0.47
GLS O94925 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
GRIA2 P42262 1/20 0.46
CSF1R P07333 2/20 0.45
ENPP2 Q13822 1/20 0.45
KCNH2 Q12809 1/20 0.43
PDGFRB P09619 1/20 0.43
KIT P10721 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT3 P36888 1/20 0.43
DDR1 Q08345 1/20 0.43
AURKB Q96GD4 1/20 0.43
KDM1A O60341 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14306286 0.85 TRPV1 (0.51) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL30791579 0.85 TRPV1 (0.51) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL22501639 0.83 TRPV1 (0.52) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL19318505 0.82 PTGES (0.55) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL31236179 0.82 TRPV1 (0.51) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL27778348 0.82 RIPK1 (0.55) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL14279029 0.81 PTGES (0.56) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL30074796 0.79 TRPV1 (0.52) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL28907319 0.79 TRPV1 (0.52) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL10263975 0.79 L3MBTL1 (0.50) TRPV1NAMPTKCNQ3KCNQ2KCNQ4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US claimed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US claimed
CN-118561801-A Benzo [ d ] [1,3] dioxoles compound, preparation method and application thereof 上海医药集团股份有限公司 2024-08-30 CN disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 TRPV1 4626/4885NAMPT 1330/4885KCNQ3 3070/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 TRPV1 4559/4885NAMPT 1036/4885KCNQ3 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.